Scholarlink

Background <p>Accelerated partial breast irradiation (APBI) has shown non-inferior local control compared to whole breast irradiation, but the optimal external-beam regimen is unclear. This study compares two APBI schedules used at our institution: 38.5&#xa0;Gy in 10 twice-daily fractions and 28.5&#xa0;Gy in 5 once-daily fractions delivered every other day.</p> Methods <p>This retrospective, single-institution study includes post-menopausal women with ductal carcinoma in-situ (DCIS) and early-stage hormone receptor positive invasive breast cancer who underwent lumpectomy followed by APBI and endocrine therapy. Outcomes of interest include ipsilateral breast tumor recurrence (IBTR), disease-free survival (DFS), overall survival (OS), radiation toxicities (graded by CTCAE v5.0), and physician-reported (Harvard scale) cosmetic outcomes.</p> Results <p>A total of 399 patients were eligible: 142 in the 38.5&#xa0;Gy group and 257 in the 28.5&#xa0;Gy group. The median age was 66 years. Most patients had T1 tumors or DCIS (97.4%), were treated with 3D-conformal radiation (99.2%) in the prone position (96.0%), and initiated adjuvant endocrine therapy (86.0%). With a median follow-up of 3.4 years, 3-year IBTR was low and comparable (1% for 38.5&#xa0;Gy vs. 2% for 28.5&#xa0;Gy; <i>P</i> = 0.46). Three-year DFS was 99% vs. 98% (<i>P</i> = 0.79) and OS was 99% in both groups (<i>P</i> = 0.53). For acute toxicity, grade 1–2 dermatitis was significantly more common in the 38.5&#xa0;Gy group (61.7% vs. 28.6%, <i>P</i> &lt; 0.01). For late toxicity at 1-year post-treatment, grade 1–2 skin hyperpigmentation (79.5% vs. 32.4%, <i>P</i> &lt; 0.01) and fibrosis (81.6% vs. 51%, <i>P</i> &lt; 0.01) were significantly more common in the 38.5&#xa0;Gy group than 28.5&#xa0;Gy group, respectively. No grade ≥ 3 acute or late toxicities were observed. Cosmetic outcomes were similarly excellent. At 1 year, excellent or good cosmesis was observed in 99% of patients in the 38.5&#xa0;Gy group and 98% in the 28.5&#xa0;Gy group (<i>P</i> = 0.15), and at 3 years in 97.3% and 94.1%, respectively (<i>P</i> = 0.83).</p> Conclusions <p>Both regimens—38.5&#xa0;Gy in 10 twice-daily fractions and 28.5&#xa0;Gy in 5 once-daily fractions—delivered using 3D-conformal technique in the prone position yielded excellent 3-year outcomes. Nonetheless, the 28.5&#xa0;Gy regimen demonstrated a lower incidence of acute and late toxicity and may be preferable in this patient population given its lower skin toxicity and increased convenience. Longer follow-up is warranted to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of once daily and twice daily accelerated partial breast irradiation regimens in hormone receptor positive breast cancer: a single institution experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月23日

查看全文
  • Tanun Jitwatcharakomol,
  • Yevgeniya Gokun,
  • Sierra J. Daniel,
  • Mariella Mestres-Villanueva,
  • Rebekah L. Young,
  • Jacob M. Eckstein,
  • Therese Y. Andraos,
  • Erin H. Healy,
  • Julia R. White,
  • Jose G. Bazan Jr,
  • Pavnesh Kumar,
  • Eric R. Cochran,
  • Sasha J. Beyer,
  • Sachin R. Jhawar

摘要

Background

Accelerated partial breast irradiation (APBI) has shown non-inferior local control compared to whole breast irradiation, but the optimal external-beam regimen is unclear. This study compares two APBI schedules used at our institution: 38.5 Gy in 10 twice-daily fractions and 28.5 Gy in 5 once-daily fractions delivered every other day.

Methods

This retrospective, single-institution study includes post-menopausal women with ductal carcinoma in-situ (DCIS) and early-stage hormone receptor positive invasive breast cancer who underwent lumpectomy followed by APBI and endocrine therapy. Outcomes of interest include ipsilateral breast tumor recurrence (IBTR), disease-free survival (DFS), overall survival (OS), radiation toxicities (graded by CTCAE v5.0), and physician-reported (Harvard scale) cosmetic outcomes.

Results

A total of 399 patients were eligible: 142 in the 38.5 Gy group and 257 in the 28.5 Gy group. The median age was 66 years. Most patients had T1 tumors or DCIS (97.4%), were treated with 3D-conformal radiation (99.2%) in the prone position (96.0%), and initiated adjuvant endocrine therapy (86.0%). With a median follow-up of 3.4 years, 3-year IBTR was low and comparable (1% for 38.5 Gy vs. 2% for 28.5 Gy; P = 0.46). Three-year DFS was 99% vs. 98% (P = 0.79) and OS was 99% in both groups (P = 0.53). For acute toxicity, grade 1–2 dermatitis was significantly more common in the 38.5 Gy group (61.7% vs. 28.6%, P < 0.01). For late toxicity at 1-year post-treatment, grade 1–2 skin hyperpigmentation (79.5% vs. 32.4%, P < 0.01) and fibrosis (81.6% vs. 51%, P < 0.01) were significantly more common in the 38.5 Gy group than 28.5 Gy group, respectively. No grade ≥ 3 acute or late toxicities were observed. Cosmetic outcomes were similarly excellent. At 1 year, excellent or good cosmesis was observed in 99% of patients in the 38.5 Gy group and 98% in the 28.5 Gy group (P = 0.15), and at 3 years in 97.3% and 94.1%, respectively (P = 0.83).

Conclusions

Both regimens—38.5 Gy in 10 twice-daily fractions and 28.5 Gy in 5 once-daily fractions—delivered using 3D-conformal technique in the prone position yielded excellent 3-year outcomes. Nonetheless, the 28.5 Gy regimen demonstrated a lower incidence of acute and late toxicity and may be preferable in this patient population given its lower skin toxicity and increased convenience. Longer follow-up is warranted to confirm these findings.